These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 1531699

  • 1. Tyrosine phosphorylation of vav proto-oncogene product containing SH2 domain and transcription factor motifs.
    Margolis B, Hu P, Katzav S, Li W, Oliver JM, Ullrich A, Weiss A, Schlessinger J.
    Nature; 1992 Mar 05; 356(6364):71-4. PubMed ID: 1531699
    [Abstract] [Full Text] [Related]

  • 2. Product of vav proto-oncogene defines a new class of tyrosine protein kinase substrates.
    Bustelo XR, Ledbetter JA, Barbacid M.
    Nature; 1992 Mar 05; 356(6364):68-71. PubMed ID: 1311423
    [Abstract] [Full Text] [Related]

  • 3. Single point mutations in the SH2 domain impair the transforming potential of vav and fail to activate proto-vav.
    Katzav S.
    Oncogene; 1993 Jul 05; 8(7):1757-63. PubMed ID: 8510922
    [Abstract] [Full Text] [Related]

  • 4. Insulin-like growth factor-1 induces rapid tyrosine phosphorylation of the vav proto-oncogene product.
    Uddin S, Yetter A, Katzav S, Hofmann C, White MF, Platanias LC.
    Exp Hematol; 1996 Apr 05; 24(5):622-7. PubMed ID: 8605967
    [Abstract] [Full Text] [Related]

  • 5. Vav binds to several SH2/SH3 containing proteins in activated lymphocytes.
    Ramos-Morales F, Druker BJ, Fischer S.
    Oncogene; 1994 Jul 05; 9(7):1917-23. PubMed ID: 8208538
    [Abstract] [Full Text] [Related]

  • 6. Tyrosine phosphorylation and activation of Vav GTP/GDP exchange activity in antigen receptor-triggered B cells.
    Gulbins E, Langlet C, Baier G, Bonnefoy-Berard N, Herbert E, Altman A, Coggeshall KM.
    J Immunol; 1994 Mar 01; 152(5):2123-9. PubMed ID: 8133029
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Mutagenic analysis of Vav reveals that an intact SH3 domain is required for transformation.
    Groysman M, Nagano M, Shaanan B, Katzav S.
    Oncogene; 1998 Sep 24; 17(12):1597-606. PubMed ID: 9794237
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Tyrosine phosphorylation of adaptor protein 3BP2 induces T cell receptor-mediated activation of transcription factor.
    Qu X, Kawauchi-Kamata K, Miah SM, Hatani T, Yamamura H, Sada K.
    Biochemistry; 2005 Mar 15; 44(10):3891-8. PubMed ID: 15751964
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Vav: Captain Hook for signal transduction?
    Katzav S.
    Crit Rev Oncog; 1995 Mar 15; 6(2):87-97. PubMed ID: 8792085
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Autophosphorylation mutants of the EGF-receptor signal through auxiliary mechanisms involving SH2 domain proteins.
    Li N, Schlessinger J, Margolis B.
    Oncogene; 1994 Dec 15; 9(12):3457-65. PubMed ID: 7970705
    [Abstract] [Full Text] [Related]

  • 16. The protein tyrosine kinase ZAP-70 can associate with the SH2 domain of proto-Vav.
    Katzav S, Sutherland M, Packham G, Yi T, Weiss A.
    J Biol Chem; 1994 Dec 23; 269(51):32579-85. PubMed ID: 7798261
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The SH2 and SH3 domain-containing Nck protein is oncogenic and a common target for phosphorylation by different surface receptors.
    Li W, Hu P, Skolnik EY, Ullrich A, Schlessinger J.
    Mol Cell Biol; 1992 Dec 23; 12(12):5824-33. PubMed ID: 1333047
    [Abstract] [Full Text] [Related]

  • 19. Vav family proteins couple to diverse cell surface receptors.
    Moores SL, Selfors LM, Fredericks J, Breit T, Fujikawa K, Alt FW, Brugge JS, Swat W.
    Mol Cell Biol; 2000 Sep 23; 20(17):6364-73. PubMed ID: 10938113
    [Abstract] [Full Text] [Related]

  • 20. Functional and physical interactions of Syk family kinases with the Vav proto-oncogene product.
    Deckert M, Tartare-Deckert S, Couture C, Mustelin T, Altman A.
    Immunity; 1996 Dec 23; 5(6):591-604. PubMed ID: 8986718
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.